Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | CASP6 | P55212 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.33 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1559642 | 0.84 | KDM4E (0.45) | KDM4EPOLBALDH1A1MAPTGAA | |
| SCHEMBL1559446 | 0.83 | KDM4E (0.47) | KDM4EPOLBALDH1A1MAPTGAA | |
| SCHEMBL1675827 | 0.83 | KDM4E (0.44) | KDM4EPOLBALDH1A1MAPTGAA | |
| SCHEMBL1675855 | 0.82 | KDM4E (0.46) | KDM4EPOLBALDH1A1MAPTGAA | |
| SCHEMBL1560653 | 0.81 | KDM4E (0.42) | KDM4EPOLBALDH1A1MAPTGAA | |
| SCHEMBL1675833 | 0.80 | KDM4E (0.44) | KDM4EPOLBALDH1A1MAPTGAA | |
| SCHEMBL13611600 | 0.80 | KDM4E (0.44) | KDM4EPOLBALDH1A1MAPTGAA | |
| SCHEMBL1203989 | 0.80 | POLB (0.46) | KDM4EPOLBALDH1A1MAPTGAA | |
| SCHEMBL13611610 | 0.79 | KDM4E (0.46) | KDM4EPOLBALDH1A1MAPTGAA | |
| SCHEMBL3988453 | 0.78 | POLB (0.48) | KDM4EPOLBALDH1A1MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2564850-B1 | Polo-like kinase inhibitors | TAKEDA PHARMACEUTICAL (JP) | 2014-08-13 | — | — | EP | disclosed |
| EP-2564850-B1 | Polo-like kinase inhibitors | TAKEDA PHARMACEUTICAL (JP) | 2014-08-13 | — | — | EP | disclosed |
| EP-2564850-A1 | Polo-like kinase inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2013-03-06 | — | — | EP | disclosed |
| EP-2564850-A1 | Polo-like kinase inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2013-03-06 | — | — | EP | disclosed |
| US-8318727-B2 | Polo-like kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-27 | — | — | US | disclosed |
| US-8318727-B2 | Polo-like kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-27 | — | — | US | disclosed |
| US-8318727-B2 | Polo-like kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-27 | — | — | US | disclosed |
| US-8026234-B2 | Polo-like kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-09-27 | — | — | US | disclosed |
| US-8026234-B2 | Polo-like kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-09-27 | — | — | US | disclosed |
| US-8026234-B2 | Polo-like kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-09-27 | — | — | US | disclosed |
| US-20110201818-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-18 | — | — | US | disclosed |
| US-20110082111-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-04-07 | — | — | US | disclosed |
| US-20110082111-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-04-07 | — | — | US | disclosed |
| US-20110082111-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-04-07 | — | — | US | disclosed |
| EP-2205241-A1 | POLO-LIKE KINASE INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2010-07-14 | — | — | EP | disclosed |
| US-20090281092-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090281092-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090281092-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-12 | — | — | US | disclosed |
| WO-2009042711-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-02 | — | — | WO | disclosed |
| WO-2009042711-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281092-A1 | POLO-LIKE KINASE INHIBITORS | PLK1, PLK2, POLK | KDM4E 2195/4885POLB 40/4885ALDH1A1 4009/4885 |
| US-20110201818-A1 | POLO-LIKE KINASE INHIBITORS | PLK1, PLK2, POLK | KDM4E 2195/4885POLB 40/4885ALDH1A1 4009/4885 |
| US-20110082111-A1 | POLO-LIKE KINASE INHIBITORS | PLK1, PLK2, POLK | KDM4E 2195/4885POLB 40/4885ALDH1A1 4009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.